Cochlear Ltd - Asset Resilience Ratio
Cochlear Ltd (COH) has an Asset Resilience Ratio of 9.76% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Cochlear Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Cochlear Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Cochlear Ltd total assets.
Liquid Assets Composition Over Time
This chart breaks down Cochlear Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore COH strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$275.70 Million | 9.76% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$275.70 Million | 9.76% |
Asset Resilience Insights
- Limited Liquidity: Cochlear Ltd maintains only 9.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Cochlear Ltd Industry Peers by Asset Resilience Ratio
Compare Cochlear Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Medartis Holding AG
SW:MED |
Medical Devices | 0.00% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236 |
Medical Devices | 25.01% |
|
Mediantechn
PA:ALMDT |
Medical Devices | 0.45% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Cochlear Ltd (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Cochlear Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 9.76% | AU$275.70 Million ≈ $195.08 Million |
AU$2.83 Billion ≈ $2.00 Billion |
-12.69pp |
| 2024-06-30 | 22.45% | AU$616.30 Million ≈ $436.07 Million |
AU$2.75 Billion ≈ $1.94 Billion |
-2.71pp |
| 2023-06-30 | 25.16% | AU$646.30 Million ≈ $457.30 Million |
AU$2.57 Billion ≈ $1.82 Billion |
-3.16pp |
| 2022-06-30 | 28.32% | AU$698.10 Million ≈ $493.95 Million |
AU$2.47 Billion ≈ $1.74 Billion |
+2.07pp |
| 2021-06-30 | 26.25% | AU$636.90 Million ≈ $450.65 Million |
AU$2.43 Billion ≈ $1.72 Billion |
-9.75pp |
| 2020-06-30 | 36.00% | AU$930.00 Million ≈ $658.03 Million |
AU$2.58 Billion ≈ $1.83 Billion |
+3.84pp |
| 2019-06-30 | 32.16% | AU$443.60 Million ≈ $313.88 Million |
AU$1.38 Billion ≈ $975.87 Million |
+26.53pp |
| 2018-06-30 | 5.64% | AU$65.20 Million ≈ $46.13 Million |
AU$1.16 Billion ≈ $818.58 Million |
-3.87pp |
| 2017-06-30 | 9.50% | AU$107.97 Million ≈ $76.40 Million |
AU$1.14 Billion ≈ $804.00 Million |
+8.31pp |
| 2016-06-30 | 1.20% | AU$11.45 Million ≈ $8.10 Million |
AU$957.36 Million ≈ $677.40 Million |
+0.76pp |
| 2015-06-30 | 0.44% | AU$3.85 Million ≈ $2.73 Million |
AU$875.40 Million ≈ $619.40 Million |
+0.41pp |
| 2010-06-30 | 0.03% | AU$204.00K ≈ $144.34K |
AU$751.72 Million ≈ $531.89 Million |
-- |
About Cochlear Ltd
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor… Read more